PI3K-IN-70
PI3K-IN-70 is a selective, ATP-competitive PI3Kα, PI3Kβ, and PI3Kδ inhibitor with IC50 values of 1978 nM, 1873 nM, and 146 nM, respectively. PI3K-IN-70 induces Autophagy and blocks epithelial-mesenchymal transition. PI3K-IN-70 in combination with Enzalutamide (HY-70002) synergistically inhibits tumor growth and lung metastasis in an AR-high breast cancer xenograft model. PI3K-IN-70 can be used for research on prostate cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 3000541-68-1
- Fòrmula: C32H24F2O4
- Peso molecular:510.53
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
IC50 & Target
[1]|
PI3Kα 1978 nM (IC50) |
PI3Kβ 1873 nM (IC50) |
PI3Kδ 146 nM (IC50) |
PI3Kγ 12212 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
9.76 μM
|
Cytotoxicity against human MDA-MB-231 breast cancer cells assessed as viability reduction by MTT assay.
Cytotoxicity against human MDA-MB-231 breast cancer cells assessed as viability reduction by MTT assay.
|
s41420-026-03389-0 |
| MDA-MB-453 | IC50 |
64.47 μM
|
Cytotoxicity against human MDA-MB-453 breast cancer cells assessed as viability reduction by MTT assay.
Cytotoxicity against human MDA-MB-453 breast cancer cells assessed as viability reduction by MTT assay.
|
s41420-026-03389-0 |
| MDA-MB-453 | IC50 |
36.51 μM
|
Cytotoxicity against AR-knockdown MDA-MB-453 breast cancer cells assessed as viability reduction by MTT assay.
Cytotoxicity against AR-knockdown MDA-MB-453 breast cancer cells assessed as viability reduction by MTT assay.
|
s41420-026-03389-0 |
| MDA-MB-453 | IC50 |
35.04 μM
|
Cytotoxicity against UBE2C-knockdown MDA-MB-453 breast cancer cells assessed as viability reduction by MTT assay.
Cytotoxicity against UBE2C-knockdown MDA-MB-453 breast cancer cells assessed as viability reduction by MTT assay.
|
s41420-026-03389-0 |
| PC-3 | IC50 |
16.05 μM
|
Cytotoxicity against human PC-3 prostate cancer cells assessed as viability reduction by MTT assay.
Cytotoxicity against human PC-3 prostate cancer cells assessed as viability reduction by MTT assay.
|
s41420-026-03389-0 |
| LNCaP | IC50 |
69.22 μM
|
Cytotoxicity against human LNCaP prostate cancer cells assessed as viability reduction by MTT assay.
Cytotoxicity against human LNCaP prostate cancer cells assessed as viability reduction by MTT assay.
|
s41420-026-03389-0 |
| LNCaP | IC50 |
30.84 μM
|
Cytotoxicity against AR-knockdown LNCaP prostate cancer cells assessed as viability reduction by MTT assay.
Cytotoxicity against AR-knockdown LNCaP prostate cancer cells assessed as viability reduction by MTT assay.
|
s41420-026-03389-0 |
In Vitro
PI3K-IN-70 (5 µM) blocks EGF-induced AKT activation in MDA-MB-231 cells[1].
PI3K-IN-70 inhibits the viability of MDA-MB-231 and MDA-MB-453 cells with IC50 values of 9.76 µM and 64.47 µM, respectively[1].
PI3K-IN-70 (5-10 µM for MDA-MB-231; 25-50 µM for MDA-MB-453; 7-14 days) impairs the clonogenic survival of MDA-MB-231 and MDA-MB-453 cells[1].
PI3K-IN-70 (5-10 µM for MDA-MB-231; 25-50 µM for MDA-MB-453; 7 days) inhibits the tumor sphere formation and self-renewal capacity of MDA-MB-231 and MDA-MB-453 cells[1].
PI3K-IN-70 (5-10 µM for MDA-MB-231; 25-50 µM for MDA-MB-453; 0-24 h) inhibits the migration of MDA-MB-231 and MDA-MB-453 cells in the wound healing assay[1].
PI3K-IN-70 (24 h) produces a synergistic effect with AR inhibition in MDA-MB-453 cells, with an HSA score of 10.33[1].
PI3K-IN-70 combined with AR inhibition effectively downregulates the AR-UBE2C-CDC20 axis in MDA-MB-453 cells[1].
PI3K-IN-70 inhibits the viability of PC-3 and LNCaP, with IC50 values of 16.05 µM and 69.22 µM, respectively[1].
PI3K-IN-70 induces ATG5-dependent cytotoxicity in breast cancer cells, as ATG5 deficiency partially reverses PI3K-IN-70-induced inhibition of viability and migration/invasion[1].
PI3K-IN-70 induces autophagy-dependent cytotoxicity in PC-3 and LNCaP prostate cancer cells[1].
PI3K-IN-70 inhibits EMT and the UBE2C/CDC20 axis in LNCaP cells while releasing autophagy[1].
In the AR-low MDA-MB-453 background, PI3K-IN-70-responsive genes are enriched in cell cycle pathways, among which UBE2C is identified as a key candidate gene[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231
-
Concentration:2.5, 5, and 10 µM
-
Incubation Time:24 h
-
Result:Dose-dependently suppressed phosphorylation of AKT at Ser473 and Thr308 and phosphorylation of mTOR, while total AKT and mTOR were detected.
-
Cell Line:MDA-MB-231 and MDA-MB-453
-
Concentration:MDA-MB-231: 5 and 10 µM; MDA-MB-453: 25 and 50 µM
-
Incubation Time:7-14 days
-
Result:Reduced relative colony numbers in both MDA-MB-231 and MDA-MB-453 cells.
In Vivo
PI3K-IN-70 (10 mg/kg/day; daily), combined with Enzalutamide, most effectively suppresses lung metastasis in the MDA-MB-453-Luc tail-vein model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6-8 weeks old)[1]
-
Dosage:10 mg/kg/day
-
Administration:daily
-
Result:Modestly delayed tumor growth by in vivo bioluminescence imaging relative to vehicle.
The combination with Enzalutamide exerted the most profound tumor suppression among groups.
Immunohistochemistry showed that the combination reduced Ki-67 and MMP2 positivity and enhanced E-cadherin positivity.
-
Animal Model:BALB/c nude (female, 6-8 weeks old)[1]
-
Dosage:10 mg/kg/day
-
Administration:daily
-
Result:The combination with Enzalutamide minimized pulmonary tumor burden and metastatic nodule formation, outperformed individual treatments, reduced ex vivo lung bioluminescence signal, and preserved lung architecture.
- Autophagy
- Patient-Derived Xenograft (PDX)
- Tail-Vein Experimental Metastasis Xenograft
- Patient-Derived Orthotopic Xenograft (PDOX)
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Lysosome and acidic-vesicle live-cell staining
- Subcutaneous Cell-Line-Derived Xenograft
- Macroautophagy Solutions
- Breast Cancer Modeling
- Orthotopic Cell-Line Xenograft
- Intraperitoneal/Peritoneal Dissemination Xenograft
Chemical Information
-
No. CAS 3000541-68-1
-
Peso molecular 510.53
-
Fòrmula C32H24F2O4
-
SMILES
O=C1C(C2=CC=CC=C2)=C(C(CC(F)(F)C(OC)=O)C3=CC=C(C4=CC=CC=C4)C=C3)OC5=CC=CC=C51
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)